MCK McKesson Corporation

Q3 2025 10-Q

Filed: Nov 6, 2025Period ending Sep 30, 2025

Consumer Staples

Wholesale-Drugs, Proprietaries & Druggists' SundriesSEC EDGAR

McKesson Corporation (MCK) 10-Q quarterly report for Q3 2025, filed with SEC EDGAR on Nov 6, 2025 for the fiscal period ending Sep 30, 2025. This page provides AI-powered analysis including management discussion & analysis (MD&A), risk factor updates, and key quarterly financial data such as revenue and net income extracted from XBRL.

AI Filing Analysis
Q3 2025 10-Q

Management Discussion & Analysis

• Revenue $103.2B Q1 FY2025, up 10% YoY from $93.7B; 16% increase for six months to $201.0B vs $172.9B prior year
• Operating margin improved across segments: North American Pharmaceutical 0.99% vs 0.43% YoY; Oncology & Multispecialty 2.76% vs 2.18%

+3 more insights

Risk Factors

• New risks from increased regulatory uncertainty and government actions noted as potential future goodwill impairment triggers
• Updated litigation risk: $108M estimated opioid-related claims liability impacting six months ended Sept 30, 2025, down from prior $108M in 2024

+3 more insights

Quarterly Financial Summary
XBRL

Revenue

$95.3B

Net Income

$879M

Gross Margin

3.4%

Operating Margin

1.3%

Net Margin

0.9%

ROE

-67.7%

Total Assets

$84.2B

Source: XBRL data from McKesson Corporation Q3 2025 10-Q filing on SEC EDGAR. All figures in USD.

Other McKesson Corporation Quarterly Reports

Q4 2025 10-Q

Get deeper insights on McKesson Corporation

Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.